Elekta AB Class B
Recent
price
P/E
ratio
div
yld
4.29%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Elekta AB (publ) is a Sweden-based medical technology company specializing in the development, manufacturing, and sale of clinical solutions for the treatment of cancer and brain disorders. Its core products include advanced radiation therapy and radiosurgery systems such as linear accelerators (including the recently launched Elekta Evo, a CT-adaptive and AI-powered linac), the Leksell Gamma Knife for stereotactic radiosurgery, brachytherapy treatment solutions including applicators like the Rotterdam, and comprehensive clinical software systems like Elekta ONE that enhance workflow efficiency across cancer care. The company also offers products for image-guided radiation therapy and stereotactic radiosurgery that enable precise tumor and functional target treatment while sparing healthy tissue. Headquartered in Stockholm, Sweden, Elekta operates globally in more than 120 countries with around 4,700 employees. Recent major changes include the launch of the Elekta Evo linear accelerator and expansion of the Elekta ONE software suite, which together aim to drive higher personalization and productivity in radiation therapy. Elekta also acquired Philips Healthcare's Pinnacle Treatment Planning System patent portfolio to strengthen its software offerings. The company expanded operational presence by acquiring assets from its distributor in Croatia, enhancing market position and service delivery in Southeast Europe. Further strategic partnerships include an alliance with GE Healthcare's MIM Software to advance cancer care solutions. Elekta continues to innovate with products like the Elekta Esprit for neuro treatment and Elekta Harmony linac, maintaining its leadership in precision radiation therapy and clinical management for oncology and neurology. Founded in 1972, Elekta serves healthcare providers with sophisticated medical devices and software solutions aimed at improving, prolonging, and saving lives through precision cancer and brain disorder treatment. The company is listed on Nasdaq Stockholm under the ticker EKTA-B.ST. Its product portfolio spans radiation therapy equipment, radiosurgery devices, brachytherapy solutions, and integrated clinical software, targeting oncology centers, hospitals, and specialized clinics worldwide. Elekta's continued investment in innovation, strategic acquisitions, and market expansion positions it as a leading global player in the medical technology industry focused on cancer treatment and neurological disorders.
Company News
Elekta AB (publ) (EKTAY) Q1 2027 Earnings Call Transcript
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
Elekta AB (publ) (EKTAY) Q4 2026 Earnings Call Transcript
Elekta AB: Tricky, But With A Latent Upside
Elekta AB (publ) (EKTAY) Q3 2026 Earnings Call Transcript
Analyzing Anteris Technologies Global (NASDAQ:AVR) and Elekta (OTCMKTS:EKTAY)
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology
Elekta AB (publ) (EKTAY) Q2 2026 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q1 2026 Earnings Call Transcript
New Strong Sell Stocks for July 24th
Elekta AB: Latent Growth And A Recurring Base
Elekta AB (publ) (EKTAF) Q4 2025 Earnings Call Transcript
Should Value Investors Buy Elekta (EKTAY) Stock?
Elekta AB (publ) (EKTAF) Q3 2025 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q2 2025 Earnings Call Transcript
Are Investors Undervaluing Elekta (EKTAY) Right Now?
Is Elekta (EKTAY) Stock Undervalued Right Now?
Is Elekta (EKTAY) a Great Value Stock Right Now?
Should Value Investors Buy Elekta (EKTAY) Stock?